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Summary at a glance 
We demonstrate that the role of cyclooxygenase enzymes in arachidonic acid 
metabolism is altered in the nasal mucosa of aspirin-intolerant asthmatic patients. This 
suggests that abnormalities in cyclooxygenase enzymes are present in all the nasal 
mucosa of these patients. Our results provide further support to the consensus term of 
rhinosinusitis. 
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ABSTRACT 
Background and objective: Anomalies in the regulation of cyclooxygenase (COX)-1 
and-2 have been described in nasal polyps of aspirin-induced asthma (AIA). Whether 
these anomalies are specific to nasal polyps or affect all the nasal mucosa (NM) of 
upper airways is still unclear. The objective of this study was to compare the COX 
pathway in NM of AIA patients with the NM of control subjects. 
Methods: Fibroblasts were isolated from NM of 5 AIA patients (AIA-NM) and 5 
control subjects (control-NM). Cells were treated with 10 ng/ml IL-1β for up to 72 
hours. Prostaglandin E2 (PGE2) production was measured by ELISA, expression of 
COX-1 protein by Western blot, and COX-2 protein by ELISA, Western blot and 
immunofluorescence techniques. 
Results: IL-1β increased PGE2 production and COX-1 protein expression in control-NM 
fibroblasts, but no changes were found in AIA-NM. IL-1β provoked a significant time-
dependent increase in COX-2 protein expression in control-NM fibroblasts but had a 
very mild effect on COX-2 protein expression in AIA-NM. 
Conclusions: Our data suggest that abnormalities in the COX pathway are not a 
phenomenon exclusive to nasal polyp mucosa as they are also present in all the nasal 
mucosa of AIA patients. These anomalies may be involved in the pathogenesis of 
airway inflammation and NSAID intolerance in asthma patients with chronic 
rhinosinusitis and nasal polyposis. 
 
Key words: Aspirin intolerance, cyclooxygenase, fibroblasts, nasal mucosa, 
prostaglandin E2 
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INTRODUCTION 
 
Aspirin-induced asthma (AIA) is a syndrome characterized by the association of 
asthma, chronic rhinosinusitis with nasal polyps (NP), and episodes of bronchospasm 
precipitated by non-steroidal anti-inflammatory drugs (NSAIDs).1 Although the 
mechanism responsible for AIA has not been completely elucidated, anomalies in the 
regulation of arachidonic acid (AA) metabolism seem to be involved in the adverse 
response to NSAIDs in these patients.1,2 
Upon stimulation, activated phospholipase A2 releases AA from membrane 
phospholipids. AA is then converted by enzymatic and non-enzymatic pathways into a 
large number of eicosanoids. The major enzymatic routes include the lipoxygenase (LO) 
pathway, which is responsible for the formation of leukotrienes, 15-HETE, and 
lipoxins; the cyclooxygenase (COX) pathway, involved in the formation of 
prostaglandins (PG), thromboxanes and prostacyclin; and the cytochrome P450 
pathway, responsible for the formation of 20-HETE and other metabolites.3,4 
In the human lung, the 5-LO pathway is responsible for the synthesis of cysteinyl-
leukotrienes (CysLTs). Various studies have reported that this pathway is up-regulated 
in the upper and lower airways of AIA patients. The expression of the enzyme LTC4 
synthase, which is involved in the synthesis of LTC4, is much higher in the airways of 
AIA patients than in those of aspirin-tolerant asthma patients and healthy controls.5,6 
The increased activity of the 5-LO pathway results in overproduction of CysLTs in 
AIA, which is further increased when patients are exposed to NSAIDs.7,8 
This over-expression of CysLT is a finding reported by almost all the authors who have 
studied the mechanism of AIA. However, the presence of anomalies in the regulation of 
the COX metabolism has been reported in only some of these studies, and their role in A
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the pathogenesis of AIA remains to be clarified.1,2 Accordingly, this study has focused 
solely on the COX pathway in AIA. 
The COX pathway converts AA into PGs, including PGE2, PGD2 and PGF2α. Two 
functional COX isoforms have been identified. COX-1 is constitutively expressed in 
most tissues and generates PGs which are primarily involved in the regulation of 
homeostatic functions. COX-2 is inducible by several cytokines and growth factors, 
including interleukin (IL)-1β and tumor necrosis factor-α .3,4 
Various anomalies have been reported in the COX pathway of AIA.1,2  Low production 
of PGE2 associated with down-regulated expression of COX enzymes has been reported 
in NP tissue and in both fibroblasts and epithelial cells from the NP of AIA patients,9-15 
suggesting that abnormalities in AA metabolism could play a role in AIA etiology. 
However, there are no reports to date of such alterations in the NM of AIA patients. In 
contrast to the results obtained in NP, studies using bronchial biopsies and cultured 
bronchial fibroblasts from AIA and aspirin-tolerant asthma have not been able to find 
any differences in the expression of COX-1 and COX-2 when compared to healthy 
controls.5,16 There are no clear explanations for the reported discrepancies between the 
results obtained in the upper and lower airways. These discrepancies might be due, at 
least in part, to the fact that the regulation of COX enzymes has been extensively 
studied by comparing NP with NM from control subjects10-14 but has yet to be studied 
by comparing NM from AIA patients with NM from control subjects. In other words, 
since inflammatory polyps are structures found in the upper airways but never seen in 
the lower airways, it is reasonable to ask whether the anomalies reported in the 
regulation of COX-1 and COX-2 expression in the upper airways are specific to NP and 
therefore not representative of either the NM surrounding the NP structure or the 
bronchial mucosa.  A
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The objective of this study was to compare the COX pathway in the NM of AIA 
patients with the NM of control subjects. With this aim in mind, we studied and 
compared PGE2 production and COX-1 and 2 expression in fibroblasts derived from the 
NM of both AIA and control subjects. 
 
METHODS 
 
Study population 
We obtained NM specimens from 5 non-asthmatic subjects with either septal deviation 
or turbinate hypertrophy who had undergone nasal corrective surgery (control-NM). All 
the control subjects had taken aspirin or NSAIDs at clinical dosage without any 
untoward reactions (asthma and/or rhinitis, urticaria, angioedema or anaphylaxis). NM 
specimens were also collected from 5 asthmatic patients with chronic rhinosinusitis and 
aspirin intolerance (AIA-NM) who had undergone endoscopic sinus surgery. The 
clinical and demographic characteristics of the subjects are shown in Table 1. The 
diagnosis of aspirin intolerance was confirmed by lysine-aspirin nasal challenge, as 
previously described.17 None of the control subjects had had any oral or intranasal 
corticosteroid treatment for at least one month before surgery. None of the patients had 
any upper airway infection in the 2 weeks before surgery. All patients gave informed 
consent to participate in the study, which was approved by the Scientific and Ethics 
Committee of our Institution. 
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Tissue handling and cell culture 
NM tissue was cut into 3 x 3 mm fragments and placed in six-well plates (NUNC, 
Wiesbaden, Germany) containing Dulbecco's modified Eagle's media (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 µg/ml 
streptomycin (Invitrogen, Carlsbad, California, USA) and 2 µg/ml amphotericin B 
(Sigma, St Louis, MO, USA). Cultures were placed in a 5% CO2 humidified incubator 
at 37ºC. Once the fibroblasts had grown, tissue fragments were removed and the first 
passage was performed by adding 0.05% trypsin/0.02% ethylenediaminetetraacetic acid 
(Invitrogen, Carlsbad, California, USA) for 5 min. The reaction was stopped with 10% 
FBS-supplemented DMEM. Cells were then centrifuged (400g, 5 min) and seeded in 
150 cm2 flasks (NUNC). At passages 3 to 7, fibroblasts were cultured in CultureSlides® 
and flasks to perform culture characterization and experimental protocols. The same 
batch of FBS was used for the whole experimental period. Mycoplasma contamination 
was tested by PCR in the cultures and all of them were negative. 
 
Culture characterization 
Culture characterization was performed by immunofluorescence for vimentin 
(fibroblasts), cytokeratins (epithelial cells) and alpha smooth muscle actin 
(myofibroblasts) in CultureSlides® incubated with serum-free media (SFM) for 24 
hours.  
 
Experimental protocols 
When cultures reached 80% confluence, FBS-supplemented media was switched to 
serum-free media (SFM) for 24 hours. Cells were then incubated with SFM in the 
presence or absence of 10 ng/ml IL-1β (R&D Systems Minneapolis, MN, USA) for A
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different times. CultureSlides® were used to study COX-2 protein expression by 
immunofluorescence. Flask culture supernatants were centrifuged (400g, 10 min at 
4ºC), sterilized through 0.22 µm filters, and stored at -80ºC until the PGE2 
concentrations were measured. Total proteins were obtained by scraping the flasks after 
two washes with cold PBS. The cells were centrifuged (1,500g, 5 min at 4ºC) and 
resuspended in 0.4 ml cold lysis buffer (CompleteTM protease inhibitor tablet in 50 ml of 
0.05 M Hepes buffer solution, 0.05% v/v Triton X-100, and 625 µM PMSF). Cells were 
sonicated twice for 15 seconds in a sonifier (Branson, Danbury, CT, USA) and 
centrifuged (12,000g, 10 min at 4ºC). Cell lysates were used to analyze protein 
expression by Western blot and ELISA. 
 
Immunofluorescence 
This technique was performed as previously reported [14]. The primary antibodies were 
against alpha-smooth muscle actin (M0851, DAKO, Glostrup, Denmark) at dilution 
1:500, vimentin at 1:100 (V5255, Sigma, Saint Louis, Missouri, USA), pan-cytokeratin 
at 1:200  (C2562, recognizing cytokeratins 1, 4, 5, 6, 8, 10, 13, 18 and 19, Sigma) or 
COX-2 (SC-1745, Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA). The 
percentage of positive cells was quantified using fluorescence microscopy.  
 
PGE2 and COX-2 ELISA 
Concentrations of PGE2 in supernatants were measured using enzyme immunoassay kits 
(Cayman Chemical, Ann Arbor, MI, USA). The assay range was 7.81-1000 pg/ml. 
COX-2 protein concentrations were measured using an enzyme-linked immunosorbent 
sandwich assay (Zymed Laboratories, San Francisco, CA, USA). The assay range was A
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2.15-275 ng/ml. The concentrations of PGE2 and COX-2 were normalized to the total 
protein content in the cell lysate from corresponding samples.  
 
Western Blot 
To analyze COX-1 and COX-2 protein expression, we performed the technique we have 
previously reported.14 The primary antibodies used were against COX-1 (SC-1752, 
Santa Cruz) and COX-2 (SC-1745, Santa Cruz) at dilution 1:1000. Immunoreactive 
bands were visualized using a chemoluminiscent method (Supersignal West Pico 
Chemiluminescent Substrate, Rockford, IL, USA). Light emissions were detected by the 
CCD Camera System LAS 3000 (Fujifilm, Tokyo, Japan). Band intensities were 
quantified with Fujifilm Image Gauge 4.0 Software and normalized by β-actin band 
intensities assessed in the same samples.  
 
Statistical analysis 
Data are reported as follows: immunofluorescence data are expressed as median and 25-
75th percentile of positive cell percentage among total cells. ELISA results are shown as 
median and 25-75th interquartile of pg of PG or ng of COX-2/µg total proteins. Finally, 
Western blot results are depicted as median and 25-75th percentile of band intensities 
normalized by β-actin. The nonparametric statistical Mann-Whitney U-test was used for 
between-group comparisons and the Wilcoxon test was used for paired comparisons, 
after confirming differences with the Friedman test. Statistical significance was set at 
P<0.05. 
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RESULTS 
 
Culture characterization 
All the cells in culture had fibroblast phenotype since 100% of cells were positive to 
vimentin. There was a total absence of epithelial cells in the fibroblast cultures since no 
cytokeratin-positive cells were found. Smears of nasal mucosa epithelial cells were used 
as a positive control (Figure 1). No significant differences were observed in the 
myofibroblast percentage in fibroblast cultures (control-NM=1.6%, 1.3-3.3; AIA-
NM=3.5%, 2.0-3.6, N=5).  
 
Prostaglandin E2 production 
There were no significant differences in the production of PGE2 at baseline in cultured 
fibroblasts derived from either control-NM or AIA-NM. Compared to SFM-treated 
cells, IL-1β significantly increased PGE2 production at 24 hours in control-NM, but had 
no effect on PGE2 secretion in fibroblasts derived from AIA-NM (Figure 2).  
 
COX expression 
COX-1 basal expression was not different between control-NM and AIA-NM. 
Compared to SFM-treated cultures, however, IL-1β induced a significant time-
dependent increase in COX-1 protein expression in control-NM fibroblasts from 24 to 
72 hours. In contrast, a tendency to decreased COX-1 expression was found in AIA-NM 
fibroblasts (Figure 3).  
COX-2 expression was measured by ELISA, Western blot and immunofluorescence 
techniques. COX-2 protein expression was not detected in SFM-treated cultures, 
because the level of the protein was under the level of detection of the ELISA. No cells A
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showed fluorescence and no detectable signals were present in Western blot. When cells 
were incubated with IL-1β, however, there was a significant time-dependent increase in 
COX-2 expression from 2 to 24 hours (measured by ELISA) in control-NM fibroblasts. 
In contrast, IL-1β had a very mild and non-significant effect on the induction of COX-2 
in AIA-NM fibroblasts (Figure 4A). Similarly, when analyzed by Western blot and 
compared to SFM treated cultures, IL-1β increased the ratio of COX-2/β-actin protein 
expression only in control-NM (Figure 4B). Finally, when studied by 
immunofluorescence, there was a significant increase in COX-2 positive cells in 
response to IL-1β in both control-NM and AIA-NM cultures. The percentage of COX-2 
positive cells in IL-1β-treated cultures was significantly higher, however, in control-NM 
than in AIA-NM fibroblasts (Figure 4C, D).  
 
DISCUSSION 
 
The main findings of our study were: (1) IL-1β markedly stimulated the production of 
PGE2 in control-NM fibroblasts but had a non-significant effect on fibroblasts obtained 
from AIA-NM; (2) IL-1β stimulation increased COX-1 protein expression in fibroblasts 
isolated from control-NM, but not in fibroblasts obtained from AIA-NM; and (3) there 
was a marked increase in COX-2 protein expression following IL-1β exposure in 
control-NM fibroblasts, but almost no effect on fibroblasts derived from AIA-NM. 
 
This is the first study to demonstrate anomalies in the COX pathway of AA metabolism 
in nasal mucosa from AIA patients. Previous studies have reported decreased 
production of PGE2 in nasal polyps – an anomaly that is even more marked in the nasal A
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polyps of patients with AIA.10,11,16 In line with this finding, various studies have 
reported a lack of up-regulation of COX-2 in nasal polyps from both aspirin-tolerant 
asthma  and AIA.11-15,18 For reasons that remain unclear, other studies have been unable 
to find any differences in the expression of COX-2 between nasal polyps and control 
nasal mucosa.6,19 As most of the studies that did not find any differences in the 
expression of COX-2 in AIA were performed with immunohistochemistry techniques, 
we used three different methods of analysis (ELISA, Western blot and 
immunofluorescence) to assess the level of COX-2 expression.  
In our study, the three methods presented similar outcomes and confirmed that COX-2 
protein is not detected in non-stimulated fibroblasts and almost fails to be up-regulated 
by inflammatory stimuli in the nasal mucosa of AIA. These results are in keeping with 
other studies showing undetectable COX-2 protein in unstimulated nasal mucosa and 
polyp fibroblasts.14 In contrast, increased expression of COX-2 has been reported in 
nasal polyps from cystic fibrosis patients, as expected in inflammatory diseases.20,21 
This observation adds further support to the notion that, for reasons that are still 
unknown, COX-2 is abnormally regulated in the nasal mucosa of patients with AIA. 
 
Previous studies suggest that an alteration in the regulation of COX-1 may also coexist 
with anomalies in the regulation of COX-2 in the nasal polyps of patients with and 
without associated AIA.14,18 In this study we report that these anomalies are also present 
in fibroblasts derived from the nasal mucosa of AIA patients. Although it is generally 
accepted that COX-1 plays a limited role in inflammatory responses, mild modifications 
can occur in the expression of the enzyme in cells and tissues when they are stimulated 
by pro-inflammatory cytokines or injury.22 The induction of COX-1 in inflammatory 
conditions might help to mitigate, at least in part, the deficient up-regulation of COX-2 A
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in the mucosa of AIA patients. However, this compensatory mechanism could not occur 
in NM fibroblasts obtained from AIA patients as COX-1 is not induced by IL-1β. 
 
PGE2 exerts various anti-inflammatory and anti-fibrotic effects, including suppression 
of eosinophil infiltration, reduction of CysLT release, inhibition of fibroblast 
proliferation, myofibroblast transformation and collagen synthesis.23. The limited 
production of PGE2 found in the NM of AIA patients may contribute to the 
intensification of the inflammatory process in their airways and may account for the 
reported association of aspirin intolerance with increased asthma and nasal-polyp 
severity.10,24,25 
 
Moreover, when the COX-2 and PGE2 concentrations obtained by ELISA in cultures 
treated with IL-1β were compared, the values obtained in the NM of AIA were similar 
to those previously reported in NP of AIA patients14, indicating that these alterations are 
present to a similar degree in all the nasal mucosa of AIA patients. 
 
In contrast, our study reported down-regulation of arachidonic acid metabolism in 
fibroblasts of nasal mucosa from AIA patients. In keeping with our findings, several 
studies have already reported that the COX pathways are also abnormally regulated in 
nasal9 and bronchial26 epithelial cells from aspirin-sensitive asthmatics. 
 
The mechanisms responsible for the reported alterations in the regulation of COX-2 
found in our study remain to be clarified. It is well known that inflammatory stimuli 
induce cellular responses through the activation of mitogen-activated protein kinases 
(MAPKs), and that COX-2 gene expression is also regulated by the action of A
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transcription factors such as NF-κB and C/EBP, among others. The role of these 
proteins has recently been studied in AIA-NP fibroblasts and showed no differences in 
MAPK phosphorylation and transcription factor nuclear translocation, compared to 
control nasal mucosa cells.27 These findings suggest that the mechanisms involved in 
COX down-regulation should be related to other mechanisms, such as transcription 
factor bindability to gene promoter, the activity of histone acetyltransferases and 
deacetylases, and mRNA stability. 
 
Furthermore, the absence of any differences in the myofibroblast percentage in cultures 
suggests that changes in cell phenotype do not play a role in the COX pathway 
abnormalities found in our study. 
 
Finally, our findings, along with data from previous studies showing that IL-5 and ECP 
levels are increased in both sinusal (ethmoidal) and nasal (lower turbinate) samples 
from patients with chronic rhinosinusitis and NP,28 give further support to the consensus 
term of rhinosinusitis recommended by the European Position Paper on Rhinosinusitis 
and Nasal Polyps (EP3OS).29 
 
In conclusion, we found significant differences in the regulation of PGE2, COX-1 and 
COX-2 in the nasal mucosa fibroblasts of patients with AIA. Our data suggest that 
abnormalities in the COX pathway are present in all the nasal mucosa of AIA patients 
and are not exclusively confined to the nasal polyp mucosa. This study also 
demonstrates that the nasal mucosa of AIA patients cannot be used as surrogate of 
healthy nasal mucosa. 
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Table 1. Epidemiological characteristics of control subjects and AIA patients. 
 
Characteristics Control-NM NM-AIA 
Fibroblast cultures, N 5 5 
Age, years (mean±sem)  32.2±4.2 45.2±4.0 
Female, N (%) 1 (20) 3 (60) 
Asthma, N (%) 0 (0) 5 (100) 
Aspirin intolerance, N (%) 0 (0) 5 (100) 
STP positive, N (%)  1 (20) 0 (0) 
Blood eosinophilia, % (mean±sem) 1.7±0.5 9.8±1.7 
CRS with nasal polyps, N (%) 0 (0) 5 (100) 
Intranasal corticosteroid, N (%) 0 (0) 3 (60) 
 
AIA, aspirin-intolerant asthmatic. 
CRS, chronic rhinosinusitis. 
NM, nasal mucosa. 
SPT, skin prick test. 
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Figure Legends 
Figure 1. Culture characterization.  
 
Representative immunofluorescent staining in control nasal mucosa fibroblasts. A) 
Fibroblast phenotype of cells in culture was confirmed by the presence of vimentin 
fibers. B) Myofibroblast phenotype of cells in culture was confirmed by the detection of 
α-smooth muscle actin fibers. C) Absence of epithelial cells demonstrated by the 
absence of cytokeratin staining in cultures. Original magnification x 200. 
 
Figure 2. Time course of IL-1β effects on PGE2 protein production  
Fibroblasts were incubated in serum-free media with IL-1β at 10 ng/ml for 4 and 24 
hours. PGE2 (N=5) concentration was measured by ELISA. Wilcoxon signed-rank test 
was used for analysis. * P<0.05 compared to non-stimulated cells. AIA, aspirin-induced 
asthma; NM, nasal mucosa. 
 
Figure 3. Effects of IL-1β on COX-1 protein expression.  
Fibroblasts were incubated in serum-free media with IL-1β at 10 ng/ml for up to 72 
hours (N=5). COX-1 protein expression was analyzed by Western blot. Mann-Whitney 
U-test was used for between-group comparisons and Wilcoxon test for paired 
comparisons. *, P<0.05 compared to non-stimulated cells (ratio COX-1/β-actin=1); †, 
P<0.05 and ††, P<0.01 compared to IL-1β−treated control-NM. AIA, aspirin-induced 
asthma; NM, nasal mucosa. 
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Figure 4. Effects of IL-1β on COX-2 protein expression.  
Fibroblasts were incubated in serum-free media with IL-1β at 10 ng/ml (N=5). A) Time 
course of IL-1β on COX-2 protein expression analyzed by ELISA. Immunofluorescence 
(B) and Western blot (C) analysis of COX-2 protein expression in cultures incubated for 
24 hours with IL-1β. (D) Representative COX-2 detection by immunofluorescence and 
Western blot in fibroblast cultures. Mann-Whitney U-test was used for between-group 
comparisons and Wilcoxon test for paired comparisons. *, P<0.05 compared to non-
stimulated cells; † P<0.05 compared to IL-1β-treated control-NM. AIA, aspirin-induced 
asthma; NM, nasal mucosa. 
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